Use of a clinical PET/CT scanner for whole body biodistribution of intranasal nanoparticles

Whole body biodistribution of 100 nanometer sized polymer micellar nanoparticles (NPs) was determined following intranasal administration using PET/CT imaging on a clinical scanner. Nanoparticles labeled with Zirconium 89 were administered intranasally or intravenously to Sprague Dawley rats followe...

Full description

Saved in:
Bibliographic Details
Published inarXiv.org
Main Authors Veronesi, Michael C, Zamora, Marta, Bhuiyan, Mohammed, Obrien-Penney, Bill, Chin Tu Chen, Vannier, Michael W
Format Paper
LanguageEnglish
Published Ithaca Cornell University Library, arXiv.org 03.04.2017
Subjects
Animals
Biocompatibility
Biomedical materials
Brain
Computed tomography
Heart
Image acquisition
In vivo methods and tests
Intestine
Liver
Lungs
Medical imaging
Nanoparticles
Nose
Organs
Polymers
Positron emission
Post-processing
Scanners
Spatial distribution
Spleen
Stomach
Tomography
Workstations
Zirconium
Online AccessGet full text

Cover

More Information
Summary:Whole body biodistribution of 100 nanometer sized polymer micellar nanoparticles (NPs) was determined following intranasal administration using PET/CT imaging on a clinical scanner. Nanoparticles labeled with Zirconium 89 were administered intranasally or intravenously to Sprague Dawley rats followed by serial ex vivo PET/CT imaging in a clinical scanner. At 30 minutes and 1 hour following intranasal delivery, the animals were sacrificed and placed in the PET/CT scanner. Images were acquired and transferred to a workstation for post-processing. 3D regions of interest were constructed. A different set of animals were used for ex vivo verification. These animals were also administered 100 nm polymer micellar NPs and sacrificed at 30 min and 1 hr following intranasal or intravenous delivery via intra-cardiac perfusion. Various organs, including brain, lungs, heart, liver, spleen, stomach and intestines, were procured following exsanguination. A gamma counter determined activity in each organ for comparison with corresponding PET/CT region of interest activity measurements. The ex vivo measurements of activity were consistent with the image-based value determinations. Use of a clinical PET/CT scanner is a feasible means to determine the temporal and spatial distribution of radiolabeled agents after intranasal and intravenous delivery. This work may allow for quantitative in vivo testing of new radionanotheranostic agents.
ISSN:2331-8422